Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) EPS (Weighted Average and Diluted): 2010-2025

Historic EPS (Weighted Average and Diluted) for Arrowhead Pharmaceuticals (ARWR) over the last 11 years, with Sep 2025 value amounting to -$0.01.

  • Arrowhead Pharmaceuticals' EPS (Weighted Average and Diluted) rose 86.86% to -$0.18 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.08, marking a year-over-year increase of 98.40%. This contributed to the annual value of -$0.01 for FY2025, which is 99.80% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported EPS (Weighted Average and Diluted) of -$0.01 as of FY2025, which was up 99.80% from -$5 recorded in FY2024.
  • Arrowhead Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at -$0.01 for FY2025, and its period low was -$5 during FY2024.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median EPS (Weighted Average and Diluted) value was -$1.92 (recorded in 2023), while the average stood at -$2.31.
  • In the last 5 years, Arrowhead Pharmaceuticals' EPS (Weighted Average and Diluted) crashed by 160.42% in 2024 and then skyrocketed by 99.80% in 2025.
  • Arrowhead Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at -$1.36 in 2021, then declined by 22.79% to -$1.67 in 2022, then dropped by 14.97% to -$1.92 in 2023, then plummeted by 160.42% to -$5 in 2024, then surged by 99.80% to -$0.01 in 2025.